Format

Send to

Choose Destination
Oncotarget. 2016 Apr 12;7(15):20704-17. doi: 10.18632/oncotarget.8007.

The long non-coding RNA EPB41L4A-AS2 inhibits tumor proliferation and is associated with favorable prognoses in breast cancer and other solid tumors.

Author information

1
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
2
Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.
3
Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, China.
4
Heilongjiang Academy of Medical Sciences, Harbin, China.

Abstract

EPB41L4A-AS2 is a novel long non-coding RNA of unknown function. In this study, we investigated the expression of EPB41L4A-AS2 in breast cancer tissues and evaluated its relationship with the clinicopathological features and prognosis of patients with breast cancer. This entailed conducting a meta-analysis and prognosis validation study using two cohorts from the Gene Expression Omnibus (GEO). In addition, we assessed EPB41L4A-AS2 expression and its relationship with the clinicopathological features of renal and lung cancers using the Cancer Genome Atlas cohort and a GEO dataset. We also clarified the role of EPB41L4A-AS2 expression in mediating cancer cell proliferation in breast, renal, and lung cancer cell lines transfected with an EPB41L4A-AS2 expression vector. We found that high EPB41L4A-AS2 expression is associated with favorable disease outcomes. Gene ontology enrichment analysis revealed that EPB41L4A-AS2 may be involved in processes associated with tumor biology. Finally, overexpression of EPB41L4A-AS2 inhibited tumor cell proliferation in breast, renal, and lung cancer cell lines. Our clinical and in vitro results suggest that EPB41L4A-AS2 inhibits solid tumor formation and that evaluation of this long non-coding RNA may have prognostic value in the clinical management of such malignancies.

KEYWORDS:

EPB41L4A-AS2; antisense lncRNA; breast cancer; prognostic value; proliferation

PMID:
26980733
PMCID:
PMC4991486
DOI:
10.18632/oncotarget.8007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center